Synthetic biology is a rapidly emerging interdisciplinary field of science and engineering that aims to redesign living systems through reprogramming genetic information. The field has catalysed global debate among policymakers and publics. Here we describe how synthetic biology relates to these international deliberations, particularly the Convention on Biological Diversity (CBD).
Synthetic biology or engineering biology is a fast-moving field that embraces and drives state-of-the-art technologies for designing and reconstructing livings systems at different scales, primarily by reprogramming cellular genetic information. As such, the field has catalysed global debate among the wider circles of legislative policymakers, including multiple international conventions, treaties, and protocols. Various international treaties and organisations are currently examining the impacts of synthetic biology and engineered gene drive systems on their respective agreements (Table 1) . One main United Nations (UN) convention of importance to synthetic biology is the UN Convention on Biological Diversity (CBD). In simple terms, the CBD has three main objectives: (i) conservation of biological diversity, (ii) sustainable use of its components, and (iii) fair and equitable sharing of benefits arising from the use of genetic resources. Since 2010, the CBD has discussed whether synthetic biology should be classified as a new and emerging issue and its objectives and activities are of considerable importance to the synthetic biology research community. For example, one objective of the CBD is to grant sovereign rights of countries over their genetic resources. Furthermore, the CBD is also deliberating whether or not new/adapted regulations are needed for synthetic biology, how access and benefits sharing agreements (ABS) should be managed with digital sequence information (DSI) and also whether or not moratoriums on synthetic biology research and/or applications to the environment should be implemented (Table 1 ). The CBD is also debating whether the products of synthetic biology should be considered under the convention, in addition to the process or technology used to produce them. The synthetic biology community should follow these deliberations closely and take the opportunity to engage directly within these processes.
In addition, similar deliberations have been underway inside the International Union for Conservation of Nature (IUCN), the world's largest and most diverse environmental network. IUCN commissioned a broad assessment addressing mandates established at its 2016 IUCN World Conservation Congress: 'Development of IUCN Policy on Biodiversity Conservation and Synthetic Biology' (WCC-2016-Res-086). This assessment has recently been released [1] .
In 2016, the Parties to the Nagoya Protocol adopted decision XIII/16, which established a science and policy-based process on DSI These policies could have a significant influence on synthetic biology research and development internationally. For example, implementation of active ABS policies on genetic information could inhibit global commercialisation of public-funded research or promote 'get-arounds' to avoid ABS, both of which are not ideal scenarios. The policies could also fundamentally challenge the very nature and ethics of biological diversity, raising practical issues around ABS and risk assessment protocols. They also could lead to a moratorium on developing synthetic biology applications like gene drive (see below and Table 1 ).
Key Issue 1: Ownership (ABS/DSI)
The International Treaty for Plant Genetic Resources for Food and Agriculture (Plant Treaty) and the Nagoya Protocol The Nagoya Protocol is an international legal agreement for the fair and equitable sharing of the benefits [access and benefit sharing (ABS)] arising from sustainable utilisation of genetic resources to conserve and protect biodiversity.
Applies to genetic resources that serve as source material for synthetic biology research.
Creates ABS framework based on traceability and transfer of material that could be undermined by use of digital sequence information. In 2017 the secretariat of the CBD commissioned a report examining the impacts of digital sequence information as it relates to the Nagoya Protocol [8] .
The study found that the use of information on genetic resources, including in synthetic biology, could create opportunities for new forms of nonmonetary and monetary benefit sharing for the
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have begun to examine the broad themes and potential implications of synthetic biology and genomic research; specifically, how evolving technological, legal, and institutional contexts surrounding the exchange and use of DSI affects its ABS frameworks.
Science and Technology Dimensions
The recent report commissioned by the Plant Treaty has a number of key findings [2] . There are three main broad themes: (i) mining plant genomic information for gene editing in agriculture, (ii) mining for use outside of agriculture, and (iii) using the plant as a 'workhorse' to produce other products. A large amount of DNA sequence data is already widely available and easily exchanged, which raises significant challenges to the ABS logic of identification and the different expectations of monitoring. With new genetic technologies, International regime recognising sovereign rights over plant genetic resources for food and agriculture. The treaty facilitates access to the genetic material of the 64 crops in the multilateral system for research, breeding, and training for food and agriculture. Those who access the materials must be from the treaty's ratifying nations and they must agree to use the materials totally for research, breeding, and training for food and agriculture. The treaty prevents the recipients of genetic resources from claiming intellectual property rights over those resources in the form in which they received them, and ensures that access to genetic resources already protected by international property rights is consistent with international and national laws. Those who access genetic materials through the multilateral system agree to share any benefits from their use through four benefit-sharing mechanisms established by the treaty. Codification of law of the sea, including activities and resources in areas beyond national jurisdiction. Provides basis for ongoing negotiation of international agreement on marine biodiversity in areas beyond national jurisdiction, including sharing of benefits from marine genetic resources.
While these discussions are in the early stages, issues around ABS, ownership, and protections are similar to the negotiations/discussions currently underway in the CBD, Nagoya, CITES, and ITPGRFA. It could have an impact on genetic resources that could serve as source material for synthetic biology research. For the synthetic biology researcher, policy developments around the availability and usage of genetic resources could affect their 'freedom to operate'. a Adapted from [1] .
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the ABS system cannot rely on the link between physical material and data to identify ownership and location, so monitoring DSI exchange is very challenging.
Other complications are the use of partial sequence combinations and duplication of sequences in multiple organisms. To encourage equitable sharing and access to genetic materials, researchers generally use ex ante investment to facilitate access to genetic material, public funding for infrastructure investment, facilitated access for research community building, structured research collaboration, and education and training. These strategies could be considered in relation to the Nagoya Protocol and Plant Treaty [3] , as both acknowledge the importance of fair and equitable sharing of benefits arising from genetic resources, through exchange of information, access to and transfer of technology, and capacity-building.
Legal Challenges in ABS

Key Issue 2: Biocontainment
In some cases, synthetic biology applications could ultimately involve environmental release of living modified organisms (LMOs) that would interfere with evolution and natural biodiversity [4] (see below). To address this, a number of novel biocontainment strategies have been described, although their utility is still under debate [4, 5] . Several use auxotrophy, which limits a cell's ability to survive in the absence of defined chemical or nutrients.
Others involve genetic 'kill-switches', which control the viability of cells in response to defined internal or external stimuli. In contrast, physical containment directly limits contact of LMOs with the surrounding environment. The release of LMOs directly into the environment is a central topic within the CBD. Concerns are based around lack of predictable organism behaviour and influence on its surroundings. Certain criteria would need to be met to ensure the LMO would not restrict or outcompete native organisms, nor interfere with the natural evolutionary process. A major problem is the adaptive response of living organisms to their environment where, to survive, cells can evolve escape mechanisms such as mutational drift or horizontal gene transfer, or acquire essential nutrients from the environment [5] .
Key Issue 3: Interference with Evolution
Synthetic biologists directly engage with molecular evolution, from simple genetic point mutations to whole gene deletions, additions, and replacement. More recently, work has expanded to de novo genome synthesis as a result of decreasing DNA costs and the ease of large-scale DNA assembly (e.g., bacterial genomes and yeast chromosomes).
There are now a range of reverse genetics strategies available in the synthetic biologist's toolkit, with the gene drive approach (Box 1) causing particular concern within the CBD and other international conventions. Resolution of these concerns could result in a moratorium on the release into the environment of engineered organisms for specific applications.
Concluding Remarks
Synthetic biology has the potential to catalyse a new biotechnology revolution, but with these opportunities comes a duty to ensure safety. There is now an urgent need for scientists, policy makers, and broader stakeholder communities to engage with one another to collectively evaluate and decide how synthetic biology research should be conducted, with the aim of conserving biological diversity whilst providing benefits to all. We strongly recommend that the synthetic biology community monitor the CBD debates, which will include an opportunity to review the findings of the ad hoc technical expert group of synthetic biology and participate in future online forums on synthetic biology and DSI (refer to the UN Portal on Synthetic Biology for more information: https:// bch.cbd.int/synbio/).
Box 1. Gene Drives
A gene drive is a system of biased inheritance where the ability of a genetic element to pass from a parent organism to its offspring through sexual reproduction is enhanced. Unlike the population dynamics of normal genomic alterations, gene drive systems promote the spread of genetic elements through populations by ensuring inheritance at a higher frequency than Mendelian segregation would predict [9] . Of particular relevance is the Cas9-mediated gene drive study of the malaria vector mosquitoes Anopheles stephensi and Anopheles gambiae showing potential as an intervention in malaria control [9] . Cas9-mediated gene drives have also been demonstrated in mice [10] . Whilst this technique has potential to address global problems in health, agriculture, and conservation, the capacity to alter wild populations outside the laboratory has caused significant concerns [11, 12] . Therefore, it is essential to ensure that any self-propagating system has multiple biocontainment strategies in place to minimise any risk of contamination of natural biodiversity. 
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